Screener
Alto Neuroscience ANRO Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Alto Neuroscience’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001999480-26-000012
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Common stock (par value $0.0001), 500,000 shares authorized; 35,053 and 31,924 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 3 | 3 |
| Additional paid-in capital | 471,224 | 352,751 |
| Accumulated deficit | (227,871) | (201,634) |
| Accumulated other comprehensive loss | 13 | 22 |
| Total stockholders’ equity | 243,369 | 151,142 |
| Total liabilities and stockholders’ equity | $276,259 | $184,689 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Alto Neuroscience's total equity?
- Alto Neuroscience (ANRO) reported total equity of $243.37M in Q1 2026.
- How has Alto Neuroscience's total equity changed year-over-year?
- Alto Neuroscience's total equity increased by 75.0% year-over-year, from $139.1M to $243.37M.
- What is the long-term trend for Alto Neuroscience's total equity?
- Over 3 years (2022 to 2025), Alto Neuroscience's total equity has grown at a 57.9% compound annual growth rate (CAGR), from -$38.41M to $151.14M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Alto Neuroscience's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude